Cardiology

>

Latest News

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension / image credit ©Sundry Photos
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension

September 9th 2025

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds
Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds

September 8th 2025

High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults / Image credit: University of Copenhagen
High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults

September 5th 2025

Study Links Older Age and Low Fitness to Higher Risk of Arrhythmias in Healthy Adults
Study Links Older Age and Low Fitness to Higher Risk of Arrhythmias in Healthy Adults

September 4th 2025

Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial

September 2nd 2025

<1
...
6667686970
© 2025 MJH Life Sciences

All rights reserved.